

Special Issue

The Effectiveness of Pneumococcal Conjugate Vaccines

Message from the Guest Editor

Pneumococcal disease is a vaccine-preventable illness that causes a significant amount of mortality worldwide, particularly among children aged under five years old. In those who have been vaccinated, there has been a decrease in infections caused by vaccine serotypes, and the lower carriage of these serotypes has led to herd protection benefits for those who have not been vaccinated; however, the positive effects of conjugate vaccines have been undermined by the emergence and spread of non-vaccine serotypes, which threaten the efficacy of currently available vaccines. Many studies have been conducted globally to examine the effectiveness of pneumococcal conjugate vaccines; however, ongoing research is still necessary to ensure the proper surveillance of pneumococcal disease until universal pneumococcal vaccines are developed. We invite contributions of original reports, observations, or reviews on the following topics:

- Pneumococcal disease and vaccines.
- Vaccination and epidemiology.
- Current vaccines and emerging serotypes.
- Baseline studies of the PCV13 serotype before the implementation of higher-valent conjugate vaccines.

Guest Editor

Dr. Jose María Marimón

1. Biodonostia, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group, Microbiology Department, Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, 20014 San Sebastian, Spain
2. Servicio de Microbiología, Hospital Universitario Donostia, Paseo Dr Beguiristain s/n, 20014 Donostia-San Sebastián, Spain

Deadline for manuscript submissions

closed (31 May 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/192645

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).